Belimumab use, clinical outcomes and glucocorticoid reduction in patients with systemic lupus erythematosus receiving belimumab in clinical practice settings: results from the OBSErve Canada Study

To describe the characteristics of patients receiving belimumab, overall patterns of systemic lupus erythematosus (SLE) care, clinical outcomes, and changes in glucocorticoid dose following 6 months of therapy with belimumab, and healthcare resource utilization in belimumab users in Canadian clinica...

Descripción completa

Detalles Bibliográficos
Autores principales: Touma, Zahi, Sayani, Amyn, Pineau, Christian A., Fortin, Isabelle, Matsos, Mark, Ecker, George A., Chow, Andrew, Iczkovitz, Sandra
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2017
Materias:
Health Services Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5434147/
https://www.ncbi.nlm.nih.gov/pubmed/28280970
http://dx.doi.org/10.1007/s00296-017-3682-9

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5434147/
https://www.ncbi.nlm.nih.gov/pubmed/28280970
http://dx.doi.org/10.1007/s00296-017-3682-9

Ejemplares similares